|
Name: Remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid)
Type: Benzodiazepine
AKA: ['8-bromo-1-methyl-6-(2-pyridinyl)-(4S)-methyl ester', 'benzenesulfonate (1:1) and also', 'methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1', '2a][1', '4]benzodiazepin4yl]propanoate benzenesulfonic acid']
![Remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid) image](https://grammasearch.com/dev/v2/aiimages/remimazolam_%284h-imidazol%5B1%2C2-a%5D%5B1%2C4%5Dbenzodiazepine-4-propionic_acid%29.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![Remimazolam (4H-imidazol[1,2-a][1,4]benzodiazepine-4-propionic acid) image](/dev/v2/pages/pubchem_images/11902844.png)
|
|
IV. History
Remimazolam, a benzodiazepine, was developed in the early 2000s as an ultra-short-acting anesthetic. It was introduced to offer rapid onset and offset properties for sedation in surgical and procedural settings. Remimazolam's development reflects ongoing efforts to create more controlled and predictable anesthetic agents. Its use in medical practice has been growing, with a focus on improving patient safety and procedural efficiency.
|
|
V. Legal Information
Remimazolam, a benzodiazepine used for procedural sedation, is regulated as a pharmaceutical agent. Its status reflects its use in medical procedures and efforts to prevent misuse.
US Federal Schedule - IV
Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
Remimazolam is a benzodiazepine used for sedation in medical procedures. As a downer, it induces relaxation and amnesia. Short-term effects include sedation and reduced anxiety, while long-term use is generally safe with minimal risks. Overdose risks involve excessive sedation and respiratory depression. Safe dosing is typically guided by a healthcare provider. Recent research focuses on its effectiveness and safety profile.  |
|
VII. Psychological Effects
Remimazolam, a benzodiazepine, affects GABA-A receptors, providing sedation and anxiolysis. Immediate effects include relaxation and reduced anxiety, with effects lasting several hours. Long-term use may lead to dependence and cognitive impairments. Research indicates potential for cognitive decline and psychological dependence with prolonged use.
 |
|
VIII. Culture
Remimazolam is a newer benzodiazepine used for its sedative properties in medical procedures. It was developed in the late 20th century and has become notable for its rapid onset and short duration. Its cultural significance involves its role in modern anesthesia and sedation practices. Proponents highlight its advantages over traditional benzodiazepines, while opponents focus on its newness and the need for long-term safety data. Its use is primarily in medical and surgical settings.
 |